Foundry Partners, LLC Halozyme Therapeutics, Inc. Transaction History

Foundry Partners, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 04, 2021	SELL	$25.81 - $43.62 $4.96 Million - $8.38 Million	-192,014 Closed	0 $0
Q3 2020 Oct 23, 2020	SELL	$25.74 - $29.63 $74,877 - $86,193	-2,909 Reduced 1.49%	192,014 $5.05 Million
Q2 2020 Aug 03, 2020	BUY	$16.25 - $26.81 $3.17 Million - $5.23 Million	194,923 New	194,923 $5.23 Million

488

122M

208K

66.3K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $7.97B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Foundry Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Foundry Partners, LLC with notifications on news.